Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Edetate→

Edetate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
64-02-8
Molecular formula
C10H12N2Na4O8
Molecular weight
380.17 g/mol
Drug class
EDTA chelating agentexact salt form must be confirmed (e.g. calcium disodium edetate versus disodium edetate)
Mechanism of action
Edetate forms stable coordination complexes with divalent and trivalent metal ions. The clinical behaviour and indication depend materially on the EDTA salt: calcium disodium edetate is used for lead chelation, whereas disodium edetate has a different calcium-binding profile and can cause severe hypocalcaemia.

Sources: US DailyMed — Edetate calcium disodium injection (lead chelation) · NCBI Bookshelf — EDTA pharmacology and salt-form distinctions · PubChem — Edetate disodium (distinct salt form) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Edetate Environmental Risk Assessment (ERA) (the Edetate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.